On November 2, 2022 Regen BioPharma, Inc. (OTC-PINK: RGBP) (OTC-PINK: RGBPP), a biotechnology company advancing a diverse pre-clinical pipeline spanning cell therapies, RNA vaccines, RNA and DNA therapeutics and small molecule drugs reported that it will be presenting at the Emerging Growth Conference on November 9, 2022 (View Source) (Press release, Regen BioPharma, NOV 2, 2022, View Source [SID1234622838]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s CEO, Dr. David Koos, in real time. Please ask your questions during the event and Dr. Koos and his team will do their best to get through as many of them as possible.
"As our portfolio of therapeutics mature, I am excited that we can get our message out to the public via this conference," says Dr. David Koos, CEO and Chairman of the Company. "We have a loyal and enthusiastic shareholder base and I am always looking for ways to keep them updated on our progress."
Regen BioPharma, Inc. will be presenting from 1:45 – 2:15 Eastern time on Wednesday, November 9, 2022. Please register here to ensure you are able to attend the conference and receive any updates that are released: View Source;tp_key=8f326a607b&sti=rgbp
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com.
About the Emerging Growth Conference
The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of individual and institutional investors, as well as investment advisors and analysts.